1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Drugs In Development, 2022, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase 0, Preclinical, Discovery and Unknown stages are 3, 6, 1, 7, 2 and 1 respectively.
Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Female Sexual Dysfunction - Overview
- Female Sexual Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Female Sexual Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Female Sexual Dysfunction - Companies Involved in Therapeutics Development
- Autotelic Bio Inc
- Callitas Therapeutics Inc
- Can-Fite BioPharma Ltd
- Dare Bioscience Inc
- Endoceutics Inc
- Freya Pharma Solutions BV
- Jupiter Wellness Inc
- Kuhnil Pharmaceutical Co Ltd
- Lennham Pharmaceuticals Inc
- Palatin Technologies Inc
- S1 Biopharma Inc
- TherapeuticsMD Inc
- Thomas Advanced Medical LLC
- Viramal Ltd
- Female Sexual Dysfunction - Drug Profiles
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- apomorphine - Drug Profile
- Product Description
- Mechanism Of Action
- bremelanotide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- estradiol - Drug Profile
- Product Description
- Mechanism Of Action
- JW-500 - Drug Profile
- Product Description
- Mechanism Of Action
- KI-1120 - Drug Profile
- Product Description
- Mechanism Of Action
- KI-1128 - Drug Profile
- Product Description
- Mechanism Of Action
- phenylephrine - Drug Profile
- Product Description
- Mechanism Of Action
- prasterone - Drug Profile
- Product Description
- Mechanism Of Action
- Prime Msk Shot - Drug Profile
- Product Description
- Mechanism Of Action
- PrimePro - Drug Profile
- Product Description
- Mechanism Of Action
- S1B-3006 - Drug Profile
- Product Description
- Mechanism Of Action
- S1B-307 - Drug Profile
- Product Description
- Mechanism Of Action
- sildenafil citrate - Drug Profile
- Product Description
- Mechanism Of Action
- SIP-104 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- tadalafil - Drug Profile
- Product Description
- Mechanism Of Action
- testosterone - Drug Profile
- Product Description
- Mechanism Of Action
- testosterone - Drug Profile
- Product Description
- Mechanism Of Action
- Female Sexual Dysfunction - Dormant Projects
- Female Sexual Dysfunction - Discontinued Products
- Female Sexual Dysfunction - Product Development Milestones
- Featured News & Press Releases
- Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting
- Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting
- Oct 17, 2022: Palatin announces publication of Vyleesi (bremelanotide) fMRI study in Women with Hypoactive Sexual Desire Disorder (HSDD)
- Oct 10, 2022: Female sexual interest drug reaches tipping point with Phase III plans
- Sep 28, 2022: Freya Pharma Solutions receives early EMA scientific advice on its upcoming phase 3 clinical trial to confirm efficacy of Lybrido in women suffering from FSIAD
- Aug 29, 2022: Daré Bioscience announces interim analysis of phase 2b RESPOND Study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder
- Jul 26, 2022: Palatin announces preliminary fourth quarter Vyleesi net product revenue increased 225% over prior quarter
- Jun 29, 2022: Freya Pharma solutions announced its application for EMA scientific advice on its phase 3 clinical trial to confirm efficacy of lybrido in women suffering from FSIAD
- Apr 12, 2022: Freya Pharma Solutions announces appointment of Dr. Jan van der Mooren as chief medical officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD
- May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)
- Mar 24, 2021: Daré Bioscience announces initiation of phase 2b RESPOND study of sildenafil cream, 3.6% in women with female sexual arousal disorder
- Aug 25, 2020: Knight and TherapeuticsMD announce Health Canada approval of IMVEXXY
- Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
- Dec 11, 2019: Daré Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
- Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Female Sexual Dysfunction, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Female Sexual Dysfunction - Pipeline by Autotelic Bio Inc, 2022
- Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, 2022
- Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2022
- Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, 2022
- Female Sexual Dysfunction - Pipeline by Endoceutics Inc, 2022
- Female Sexual Dysfunction - Pipeline by Freya Pharma Solutions BV, 2022
- Female Sexual Dysfunction - Pipeline by Jupiter Wellness Inc, 2022
- Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
- Female Sexual Dysfunction - Pipeline by Lennham Pharmaceuticals Inc, 2022
- Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, 2022
- Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, 2022
- Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, 2022
- Female Sexual Dysfunction - Pipeline by Thomas Advanced Medical LLC, 2022
- Female Sexual Dysfunction - Pipeline by Viramal Ltd, 2022
- Female Sexual Dysfunction - Dormant Projects, 2022
- Female Sexual Dysfunction - Dormant Projects, 2022 (Contd..2)
- Female Sexual Dysfunction - Discontinued Products, 2022
- Number of Products under Development for Female Sexual Dysfunction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Autotelic Bio Inc
- Callitas Therapeutics Inc
- Can-Fite BioPharma Ltd
- Dare Bioscience Inc
- Endoceutics Inc
- Freya Pharma Solutions BV
- Jupiter Wellness Inc
- Kuhnil Pharmaceutical Co Ltd
- Lennham Pharmaceuticals Inc
- Palatin Technologies Inc
- S1 Biopharma Inc
- TherapeuticsMD Inc
- Thomas Advanced Medical LLC
- Viramal Ltd
